Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.75
Bid: 0.70
Ask: 0.80
Change: -0.05 (-6.25%)
Spread: 0.10 (14.286%)
Open: 0.80
High: 0.80
Low: 0.75
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

Thu, 09th Mar 2023 14:32

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - Pretax profit in 2022 jumps 78% to GBP10.3 million from GBP5.8 million in 2021, boosted by business to business division. Revenue grows 72% to GBP99.2 million from GBP57.7 million. Proposes final dividend of 1.1 pence per share, up from 0.9p a year ago. Total dividend is 2.0p per share, up 33% from 1.5p. Net cash as at December 31 grows to GBP8.0 million from GBP6.5 million. Executive Chair Stephen Hemsley says: "The excellent momentum in the B2B businesses has continued in 2023 to date, as we capture the defensive growth opportunities afforded by the group's mostly essential services, strong leadership positions in its chosen markets, and reputation for high quality, reliable services among its diversified client base. We look forward with confidence to expanding the business organically and by seeking further earnings-enhancing acquisitions."

----------

Hansard Global PLC - Isle of Man-based long-term savings provider - In six months to December 31, pretax profit grows to GBP3.1 million from GBP1.9 million a year prior. Maintains interim dividend of 1.8p per share. Net asset value per share as at December 31 falls to 15.6p from 16.7p a year ago. Anticipates sales of long-term savings products to continue to be impacted by global economic headwinds, but adds: "however, we are confident that our new product pipeline will lead to increased sales and long term growth in the business."

----------

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - In 2022, pretax loss narrows to GBP1.2 million from GBP1.8 million in 2021. Research & development costs reduce to GBP577,525 from GBP1.2 million. Company does not make revenue in 2022 or 2021. Notes delays of research grade materials due to global shortages. Says work is underway, with full results expected by the end of the second quarter of 2023.

----------

Seraphim Space Investment Trust PLC - London-based space technology investment company - Net asset value per share as at December 31 declines 7.2% to 92.74 pence per share from 99.97p at June 30. Company does not expect to recommend payouts in the near future due to its focus on achieving capital growth. In its outlook, notes innovation of Western economies regarding the impact of Russia's war in Ukraine. Chair Will Whitehorn says: "The investment manager is actively engaged with numerous investment prospects, carefully selecting those with a strong growth premise and offer the highest returns for shareholders. It is taking a cautious approach to the allocation of cash between supporting existing portfolio companies, making new investments, and managing the company's working capital until the market improves and more capital can be raised."

----------

Tlou Energy Ltd - Brisbane, Australia-based power project developer with large gas field in Botswana - In the six months to December 31, pretax loss widens to AUD2.2 million from AUD1.3 million a year ago. Employee benefits expense increases to AUD564,644 from AUD320,901. Posts an interest expense of AUD296,013 compared to none a year ago. Expenses classified as other widen to AUD1.0m million from AUD585,650. Expects work on purpose-built operations facility for 10 megawatt development at Lesedi, Botswana to be completed during 2023, with potential annual generation of about USD10 million in revenue from the project.

----------

Town Centre Securities PLC - Leeds, England based property investment and car parking operator - Net asset value as at December 31 is virtually flat at 314 pence per share, compared to 313p a year ago. It is down 7.9% from 341p at June 30, 2022. Maintains interim dividend at 2.5p per share. EPRA net tangible assets per share as at June 30 falls to 306p from 333p a year ago. Looking ahead, says that trading performance seen in the first half of financial year 2023 is performing into the opening months of calendar year 2023, with rent collections robust at 99% of amounts invoiced at the last quarter now collected. "The momentum in our car parks recovery has continued through 2022 however for those car parks that are particularly reliant on office workers, this recovery remains slow," it adds.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Mar 2020 12:15

N4 Pharma Explores Nuvec's Potential In Covid-19 Vaccine Delivery

N4 Pharma Explores Nuvec's Potential In Covid-19 Vaccine Delivery

Read more
24 Mar 2020 15:49

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
25 Feb 2020 11:42

N4 Pharma Annual Loss Narrows Amid Work To Improve Nuvec System

N4 Pharma Annual Loss Narrows Amid Work To Improve Nuvec System

Read more
25 Feb 2020 08:49

N4 Pharma narrows loss as it continues development work

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reported a smaller operating loss for 2019 on Tuesday, at ?0.95m, compared to ?1.42m in the prior year.

Read more
11 Feb 2020 14:19

N4 Pharma shares rise on partnership with Nanomerics

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has signed a 14-month research collaboration with Nanomerics to produce and test two candidate formulations using its 'Nuvec' delivery system, it announced on Tuesday.

Read more
11 Feb 2020 11:37

N4 Pharma Signs Research Collaboration Agreement With Nanomerics

N4 Pharma Signs Research Collaboration Agreement With Nanomerics

Read more
18 Sep 2019 12:04

N4 Pharma Interim Loss Widens After Non-Repeat Of Grant, Disposal Gain

(Alliance News) - N4 Pharma PLC on Wednesday said its loss widened slightly in the first half of the year, owing to grant income and a gain on an investment sale the year before which did not in a

Read more
20 Aug 2019 11:49

N4 Pharma Repeats Study And Finds Nuvec Successful At "Certain Doses"

(Alliance News) - N4 Pharma PLC on Tuesday said it has repeated the in-vivo study of Nuvec and shown it does work "when using multiple injections at certain doses".Shares in N4 at

Read more
19 Jun 2019 13:38

N4 Pharma To Start Experiments On Nuvec; Results Due In Two Months

(Alliance News) - N4 Pharma PLC on Wednesday said it will begin experiments on its Nuvec system on Friday this week with results due in around two months.Shares in N4 were up 20% at 4.30 in

Read more
12 Jun 2019 16:04

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 JuneTescoWM Morrison SupermarketsSirius MineralsJust Jack 14 Evans 17 18

Read more
21 May 2019 13:25

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

Read more
14 May 2019 12:09

N4 Pharma Loss Narrowed By Cost; Will Explore Assets Outside Nuvec

LONDON (Alliance News) - N4 Pharma PLC on Tuesday reported a narrowed loss for 2018 on lower costs and said it is exploring new opportunities while continuing work on core Nuvec drug delivery in -

Read more
15 Apr 2019 15:33

N4 Pharma reassures shareholders over future of 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the development of 'Nuvec' on Monday, following the disclosure of inconsistencies in the efficacy of Nuvec between various in vitro and in vivo studies.

Read more
15 Apr 2019 15:20

N4 Pharma Finds Issues With In Vivo Nuvec Testing And Plans Repeat

LONDON (Alliance News) - N4 Pharma PLC on Monday said it has become aware of a number of issues with the in vivo studies of its Nuvec delivery system.On Tuesday last week, N4 announced of a

Read more
9 Apr 2019 11:27

N4 Pharma Shares Sink As Nuvec Fails To Produce Response In-Vivo

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said early in-vivo tests of its Nuvec delivery system did not match positive results from in-vitro tests, causing shares to slump.Shares in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.